Group 1 - The Shanghai Stock Exchange Science and Technology Innovation Board Medical Index (科创医疗) reported a value of 805.42 points, with a monthly increase of 10.37%, a three-month increase of 13.32%, and a year-to-date increase of 11.07% [1] - The index consists of no more than 30 listed companies in the medical field selected from the Science and Technology Innovation Board, reflecting the overall performance of medical listed companies [1] - The index is based on a reference date of December 30, 2022, with a base value of 1000.0 points [1] Group 2 - The top ten weighted companies in the index are: 惠泰医疗 (9.77%), 联影医疗 (9.36%), 热景生物 (7.33%), 爱博医疗 (6.23%), 奕瑞科技 (6.09%), 南微医学 (5.69%), 心脉医疗 (4.91%), 圣湘生物 (4.6%), 海尔生物 (3.79%), and 天智航 (3.3%) [1] - The index is fully composed of companies listed on the Shanghai Stock Exchange, with the following industry breakdown: medical consumables (43.55%), medical devices (29.18%), and in vitro diagnostics (27.26%) [2] - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2]

Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index has shown mixed performance, with a recent increase of 1.89% over the past month, a decrease of 3.03% over the past three months, and a year-to-date increase of 1.35% [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.48%), United Imaging (10.13%), Aibo Medical (6.9%), Yirui Technology (6.49%), Nanwei Medical (5.37%), Shengxiang Biology (4.91%), Xinmai Medical (4.69%), Haier Biomedical (4.16%), Yahui Long (3.62%), and Aohua Endoscopy (3.59%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a 100% allocation [1] - The industry composition of the index holdings includes: medical consumables (45.40%), medical devices (33.27%), and in vitro diagnostics (21.34%) [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 2.05% increase over the past month but a 3.91% decrease over the past three months, and a year-to-date decline of 0.28% [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.71%), United Imaging (10.72%), Aibo Medical (6.92%), Yirui Technology (6.59%), Nanwei Medical (5.3%), Shengxiang Biology (4.93%), Xinmai Medical (4.6%), Haier Biomedical (4.24%), Yahui Long (3.64%), and Aohua Endoscopy (3.34%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - The industry composition of the index holdings includes 45.64% in medical consumables, 33.41% in medical devices, and 20.95% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]